Acute dopaminergic blockade augments the naloxone-induced LH rise in estrogen-treated postmenopausal women

Maturitas

Volumn 27, Issue 1, 1997, Pages 91-99

  Parra, Adalberto ^a   Barrón, Jesús ^a   Marín, Víctor A ^a   Coutiño, Blanca ^a   Belmont, Juan ^a   Coria, Irma ^a  

^a INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

Author keywords

dopaminergic tone; estrogen replacement therapy; luteinizing hormone; menopause; metoclopramide; naloxone; opioid tone; prolactin

Indexed keywords

ESTROGEN; GONADOTROPIN; LUTEINIZING HORMONE; METOCLOPRAMIDE; NALOXONE; OPIATE; PROLACTIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

DOPAMINE; DOPAMINE ANTAGONISTS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; METOCLOPRAMIDE; MIDDLE AGED; NALOXONE; POSTMENOPAUSE; PROLACTIN;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0030918383     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(97)01109-2     Document Type: Article

References (35)

1. Quigley ME, Yen SSC. The role of endogenous opiates in LH secretion during the menstrual cycle. J Clin Endocrinol Metab 1980; 51: 179-181.
2. Petraglia F, Bernasconi S, Lughetti L, et al. Naloxone-induced luteinizing hormone secretion in normal, precocious and delayed puberty. J Clin Endocrinol Metab 1986; 63: 1112-1116.
3. Yen SSC, Quigley ME, Reid RL, Ropert JF, Cetel NS. Neuroendocrinology of opioid peptides and their role in the control of gonadotropin and prolactin secretion. Am J Obstet Gynecol 1985; 152: 485-493.
4. Genazzani AR, Genazzani AD, Volpogni C, et al. Opioid control of gonadotropin secretion in humans. Hum Reprod 1993; 8: 151-153.
5. Tay SSC, Glasier AF, McNeilly AS. Effect of antagonists of dopamine and opiates on the basal and GnRH induced secretion of luteinizing hormone, follicle stimulating hormone and prolactin during lactational amenorrhea in breast-feeding women. Hum Reprod 1993; 8: 532-539.
6. García-Rubí E, Vázquez-Alemán D, Méndez JP, et al. The effects of opioid blockade and GnRH administration upon luteinizing hormone secretion in patients with anorexia nervosa during the stages of weight loss and weight recovery. Clin Endocrinol (Oxf) 1992; 37: 520-528.
7. Larrea F, Sandoval JF, Salinas E, Franco-Rodriguez VA, Méndez I, Ulloa-Aguirre A. Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinemia. Clin Endocrinol (Oxf) 1995; 43: 591-600.
8. Ulloa-Aguirre A, Méndez JP, González-Castillo A, Carranza-Líra S, Garza-Flores J, Pérez-Palacios G. Changes in the responsiveness of luteinizing hormone secretion to infusion of the opioid antagonist naloxone through male sexual maturation. Clin Endocrinol (Oxf) 1988; 29: 17-28.
9. D'Amico JF, Greendale GA, Lu JKH, Judd HL. Induction of hypothalamic opioid activity with transdermal estradiol administration in postmenopausal women. Fertil Steril 1991; 55: 754-758.
10. Casper RF, Alapin-Rubillovitz S. Progestins increase endogenous opioid peptide activity in postmenopausal women. J Clin Endocrinol Metab 1985; 60: 34-36.
11. Quigley ME, Sheehan KL, Casper RF, Yen SSC. Evidence for an increased opioid inhibition of luteinizing hormone secretion in hyperprolactinemic patients with pituitary microadenoma. J Clin Endocrinol Metab 1980; 50: 427-430.
12. Scoccia B, Schneider AB, Marut EL, Scommegna A. Pathological hyperprolactinemia suppresses hot flashes in menopausal women. J Clin Endocrinol Metab 1988; 66: 868-871.
13. Reid RL, Quigley ME, Yen SSC. The disappearance of opioidergic regulation of gonadotropin secretion in postmenopausal women. J Clin Endocrinol Metab 1983; 57: 1107-1110.
14. Shoupe D, Montz FJ, Lobo RA. The effects of estrogen and progestin on endogenous opioid activity in oophorectomized women. J Clin Endocrinol Metab 1985; 60: 178-183.
15. Leblanc H, Lachelin GCL, Abu-Fadil S, Yen SSC. Effects of dopamine infusion on pituitary hormone secretion in humans. J Clin Endocrinol Metab 1976; 43: 668-674.
16. Lachelin GL, Leblanc H, Yen SSC. The inhibitory effect of dopamine agonists on LH release in women. J Clin Endocrinol Metab 1977; 44: 728-732.
17. Rossmanith WG, Wirth U, Yen SSC. Does prolonged dopaminergic blockade alter the LH pulsatile secretion in normal cycling and postmenopausal women? Acta Endocrinol (Copenh) 1989; 121: 147-152.
18. Rossmanith WG. The neuroendocrinology of the peri and postmenopause. In: Scherbaum WA, Rossmanith WG, eds. The Endocrinology of Aging. Berlin: de Gruyter, 1995; 47-65.
19. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, et al. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992; 90: 2234-2241.
20. Quigley ME, Judd SJ, Gilliland GB, Yen SSC. Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and in women with hyperprolactinemic anovulation. J Clin Endocrinol Metab 1979; 48: 718-720.
21. Wardlaw SL, Wehrenberg WB, Ferin M, Antunes JL, Frantz AG. Effect of sex steroids on β-endorphin in hypophyseal portal blood. J Clin Endocrinol Metab 1982; 55: 877-881.
22. Petraglia F, De Leo V, Nappi C et al. Differences in the opioid control of luteinizing hormone secretion between pathological and iatrogenic hyperprolactinemic states. J Clin Endocrinol Metab 1987; 64: 508-512.
23. Parra A, Alarcon J, Gaviño F, Ramírez A, Espinosa de los Monteras A. Age-related changes in the metoclo-pramide-induced prolactin release in nulliparous women. Fertil Steril 1993; 60: 34-39.
24. Locatelli V, Petraglia F, Penalva A, Panerai AE. Effect of dopaminergic drugs on hypothalamic and pituitary immunoreactive β-endorphin concentrations in the rat. Life Sci 1983; 33: 1711-1717.
25. Nohtomi A, Itoh M, Yufu N. Effects of sulpiride treatment on the levels of immunoreactive β-endorphin in rat hypothalamic nuclei. Brain Res 1984; 300: 152-156.
26. Melis GB, Cagnacci A, Gambacciani M, Paoletti AM, Moggi L, Fioretti P. Restoration of luteinizing hormone response to naloxone in postmenopausal women by chronic administration of the antidopaminergic drug veralipride. J Clin Endocrinol Metab 1988; 66: 964-967.
27. Melis GB, Cagnacci A, Gambacciani M, Paoletti AM, Caffi T, Fioretti P. Chronic bromocryptine administration restores luteinizing hormone response to naloxone in postmenopausal women. Neuroendocrinology 1988; 47: 159-163.
28. Quigley ME, Sheehan KL, Casper RF, Yen SSC. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea. J Clin Endocrinol Metab 1980; 50: 949-954.
29. Popert JF, Quigley ME, Yen SSC. The dopaminergic inhibition of LH secretion during the menstrual cycle. Life Sci 1984; 34: 2067-2070.
30. Fuxe K, Hockfelt T, Nilsson O. Castration, sex hormones and tuberoinfundibular dopaminergic neurons. Neuroendocrinology 1969; 5: 107-110.
31. Ben-Jonathan N. Dopamine: a prolactin-inhibiting hormone. Endocrinol Rev 1985; 20: 564-589.
32. Wagner EJ, Manzanares J, Moore KE, Lookingland KJ. Neurochemical evidence that estrogen-induced suppression of kappa-opioid-receptor mediated regulation of tuberoinfundibular dopaminergic neurons is prolactin-independent. Neuroendocrinology 1994; 59: 197-201.
33. Matera C, Freda PU, Ferin M, Wardlaw SL. Effect of chronic opioid antagonism on the hypothalamic-pituitary-ovarian axis in hyperprolactinemic women. J Clin Endocrinol Metab 1995; 80: 540-545.
34. Seki K, Kato K, Shima K. Parallelism in the luteinizing hormone response to opioid and dopamine antagonists in hyperprolactinemic women with pituitary microadenoma. J Clin Endocrinol Metab 1986; 63: 1225-1228.
35. Verhelst J, Beckers A, Abs R. The effect of naloxone and metoclopramide on the secretion of luteinizing hormone in a hyperprolactinemic hypogonadotropic postmenopausal woman. Fertil Steril 1995; 64: 969-971.